Raphael J. Mannino
Keine laufenden Positionen mehr
Profil
Raphael J.
Mannino was the founder and held the position of Chief Scientific Officer & Executive VP at BioDelivery Sciences International, Inc. from 2007 to 2009.
He founded the company in 1995.
He also held the position of Director at BioVest International, Inc. in 2003.
Dr. Mannino had a former job as an Associate Professor at the University of Medicine & Dentistry of New Jersey from 1990 to 2015.
Prior to that, he was an Associate Professor at Albany Medical College from 1980 to 1990.
He started his career as an Assistant Professor at New Jersey Medical School in 1977.
Currently, Dr. Mannino is the Chief Scientific Officer & Senior Vice President at Matinas BioPharma Holdings, Inc. since 2015.
Dr. Mannino obtained his doctorate degree from The Johns Hopkins University School of Medicine in 1973.
Ehemalige bekannte Positionen von Raphael J. Mannino
| Unternehmen | Position | Ende |
|---|---|---|
| MATINAS BIOPHARMA HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 11.08.2022 |
| University of Medicine & Dentistry of New Jersey | Corporate Officer/Principal | 01.08.2015 |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | Founder | 01.01.2009 |
| Albany Medical College | Corporate Officer/Principal | 01.01.1990 |
| New Jersey Medical School | Corporate Officer/Principal | 01.01.1980 |
Ausbildung von Raphael J. Mannino
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MATINAS BIOPHARMA HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
BioDelivery Sciences International, Inc.
 BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
BioVest International, Inc.
 BioVest International, Inc. Medical SpecialtiesHealth Technology BioVest International, Inc. develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. The firm continued development, commercialization, manufacture and sale of AutovaxID and other instruments and disposables; and the commercial sale and production of cell culture products and services. The company was founded in 1981 and is headquartered in Tampa, FL. | Health Technology |
